Treating NF2 patients with the mTORC1 inhibitor RAD001 revealed cytostatic effects of delayed growth or stabilization of schwannomas and MN without tumor shrinkage (18, 19, 20), and the results of AZD2014 therapy remain under investigation. This evidence concerns the gene NF2 and neoplasm.